journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/28631197/prioritizing-future-research-on-allopurinol-and-febuxostat-for-the-management-of-gout-value-of-information-analysis
#1
Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K Choi, Karen M Kuntz, Hawre Jalal
OBJECTIVES: The aim of this study was to quantify the value of conducting additional research and reducing uncertainty regarding the cost effectiveness of allopurinol and febuxostat for the management of gout. METHODS: We used a previously developed Markov model that evaluated the cost effectiveness of nine urate-lowering strategies: no treatment, allopurinol-only fixed dose (300 mg), allopurinol-only dose escalation (up to 800 mg), febuxostat-only fixed dose (80 mg), febuxostat-only dose escalation (up to 120 mg), allopurinol-febuxostat sequential therapy fixed dose, allopurinol-febuxostat sequential therapy dose escalation, febuxostat-allopurinol sequential therapy fixed dose, and febuxostat-allopurinol sequential therapy dose escalation...
June 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28625004/distribution-weighted-cost-effectiveness-analysis-using-lifetime-health-loss
#2
Ulrikke J V Hernæs, Kjell A Johansson, Trygve Ottersen, Ole F Norheim
BACKGROUND: It is widely acknowledged that concerns for the worse off need to be integrated with the concern for cost effectiveness in priority setting, and several countries are seeking to do so. In Norway, a comprehensive framework for priority setting was recently proposed to specify the worse off in terms of lifetime loss of quality-adjusted life-years (QALYs). However, few studies have shown how to calculate such health losses, how to integrate health loss into cost-effectiveness analyses (CEAs) and how such integration impacts the incremental cost-effectiveness ratios (ICERs)...
June 17, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28620848/cost-effectiveness-of-pembrolizumab-vs-standard-of-care-chemotherapy-as-first-line-treatment-for-metastatic-nsclc-that-expresses-high-levels-of-pd-l1-in-the-united-states
#3
Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu, Vamsidhar Velcheti
OBJECTIVES: Our objectives were to evaluate the cost effectiveness of pembrolizumab compared with standard-of-care (SoC) platinum-based chemotherapy as first-line treatment in patients with metastatic non-small-cell lung cancer (NSCLC) that expresses high levels of programmed death ligand-1 (PD-L1) [tumour proportion score (TPS) ≥50%], from a US third-party public healthcare payer perspective. METHODS: We conducted a partitioned-survival model with a cycle length of 1 week and a base-case time horizon of 20 years...
June 15, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28616775/informing-reimbursement-decisions-using-cost-effectiveness-modelling-a-guide-to-the-process-of-generating-elicited-priors-to-capture-model-uncertainties
#4
Laura Bojke, Bogdan Grigore, Dina Jankovic, Jaime Peters, Marta Soares, Ken Stein
In informing decisions, utilising health technology assessment (HTA), expert elicitation can provide valuable information, particularly where there is a less-developed evidence-base at the point of market access. In these circumstances, formal methods to elicit expert judgements are preferred to improve the accountability and transparency of the decision-making process, help reduce bias and the use of heuristics, and also provide a structure that allows uncertainty to be expressed. Expert elicitation is the process of transforming the subjective and implicit knowledge of experts into their quantifiable expressions...
June 15, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28597368/health-related-resource-use-measurement-instruments-for-intersectoral-costs-and-benefits-in-the-education-and-criminal-justice-sectors
#5
REVIEW
Susanne Mayer, Aggie T G Paulus, Agata Łaszewska, Judit Simon, Ruben M W A Drost, Dirk Ruwaard, Silvia M A A Evers
BACKGROUND: Intersectoral costs and benefits (ICBs), i.e. costs and benefits of healthcare interventions outside the healthcare sector, can be a crucial component in economic evaluations from the societal perspective. Pivotal to their estimation is the existence of sound resource-use measurement (RUM) instruments; however, RUM instruments for ICBs in the education or criminal justice sectors have not yet been systematically collated or their psychometric quality assessed. This review aims to fill this gap...
June 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28560492/simulation-modelling-in-healthcare-an-umbrella-review-of-systematic-literature-reviews
#6
REVIEW
Syed Salleh, Praveen Thokala, Alan Brennan, Ruby Hughes, Andrew Booth
BACKGROUND: Numerous studies examine simulation modelling in healthcare. These studies present a bewildering array of simulation techniques and applications, making it challenging to characterise the literature. OBJECTIVE: The aim of this paper is to provide an overview of the level of activity of simulation modelling in healthcare and the key themes. METHODS: We performed an umbrella review of systematic literature reviews of simulation modelling in healthcare...
May 30, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28551858/cost-effectiveness-of-drug-treatments-for-advanced-melanoma-a-systematic-literature-review
#7
REVIEW
Darío Rubio-Rodríguez, Silvia De Diego Blanco, Maite Pérez, Carlos Rubio-Terrés
BACKGROUND: Until recently, advanced melanoma (unresectable and metastatic) has had a poor prognosis and has been treated with chemotherapy. The introduction of new treatments (BRAF and MEK inhibitors and immunotherapy) has improved overall survival and progression-free survival of some patients. OBJECTIVE: The objective of this study was to review the published evidence on the cost-effectiveness of pharmacological treatments for advanced melanoma. METHODS: A systematic literature search was conducted, without date or language restrictions, in PubMed, EMBASE, Scopus, the Cochrane Library, the UK National Institute for Health and Care Excellence databases and the Health Technology Assessment journal...
May 27, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28550592/certolizumab-pegol-for-treating-rheumatoid-arthritis-following-inadequate-response-to-a-tnf-%C3%AE-inhibitor-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#8
REVIEW
Iñigo Bermejo, Matt Stevenson, Rachel Archer, John W Stevens, Edward Goka, Mark Clowes, David L Scott, Adam Young
As part of its single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (UCB Pharma) of certolizumab pegol (CZP; Cimzia(®)) to submit evidence of its clinical and cost effectiveness for the treatment of rheumatoid arthritis (RA) following inadequate response to a tumour necrosis factor-α inhibitor (TNFi). The School of Health and Related Research Technology Appraisal Group at the University of Sheffield was commissioned to act as the independent Evidence Review Group (ERG)...
May 26, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28536955/using-discrete-choice-experiments-to-inform-the-benefit-risk-assessment-of-medicines-are-we-ready-yet
#9
Caroline M Vass, Katherine Payne
There is emerging interest in the use of discrete choice experiments as a means of quantifying the perceived balance between benefits and risks (quantitative benefit-risk assessment) of new healthcare interventions, such as medicines, under assessment by regulatory agencies. For stated preference data on benefit-risk assessment to be used in regulatory decision making, the methods to generate these data must be valid, reliable and capable of producing meaningful estimates understood by decision makers. Some reporting guidelines exist for discrete choice experiments, and for related methods such as conjoint analysis...
May 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28534254/the-cost-of-relapse-in-schizophrenia
#10
REVIEW
Mark Pennington, Paul McCrone
INTRODUCTION: Schizophrenia is a chronic and debilitating mental illness characterised by periods of relapse that require resource intensive management. Quantifying the cost of relapse is central to the evaluation of the cost effectiveness of treating schizophrenia. OBJECTIVES: We aimed to undertake a comprehensive search of the available literature on the cost of relapse. METHODS: We performed a search on multiple databases (MEDLINE, Embase, PsycINFO and Health Management Information Consortium) for any study reporting a cost of relapse or data from which such a cost could be calculated...
May 22, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28528523/sharing-is-caring-the-case-for-company-level-collaboration-in-pharmacoeconomic-modelling
#11
LETTER
Anthony J Hatswell, Fleur Chandler
No abstract text is available yet for this article.
May 20, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28488257/a-comparison-of-four-software-programs-for-implementing-decision-analytic-cost-effectiveness-models
#12
REVIEW
Chase Hollman, Mike Paulden, Petros Pechlivanoglou, Christopher McCabe
The volume and technical complexity of both academic and commercial research using decision analytic modelling has increased rapidly over the last two decades. The range of software programs used for their implementation has also increased, but it remains true that a small number of programs account for the vast majority of cost-effectiveness modelling work. We report a comparison of four software programs: TreeAge Pro, Microsoft Excel, R and MATLAB. Our focus is on software commonly used for building Markov models and decision trees to conduct cohort simulations, given their predominance in the published literature around cost-effectiveness modelling...
May 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28477220/defining-and-measuring-the-affordability-of-new-medicines-a-systematic-review
#13
REVIEW
Fernando Antoñanzas, Robert Terkola, Paul M Overton, Natalie Shalet, Maarten Postma
BACKGROUND: In many healthcare systems, affordability concerns can lead to restrictions on the use of expensive efficacious therapies. However, there does not appear to be any consensus as to the terminology used to describe affordability, or the thresholds used to determine whether new drugs are affordable. OBJECTIVES: The aim of this systematic review was to investigate how affordability is defined and measured in healthcare. METHODS: MEDLINE, EMBASE and EconLit databases (2005-July 2016) were searched using terms covering affordability and budget impact, combined with definitions, thresholds and restrictions, to identify articles describing a definition of affordability with respect to new medicines...
May 5, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28474299/evaluation-of-healthcare-interventions-and-big-data-review-of-associated-data-issues
#14
Carl V Asche, Brian Seal, Kristijan H Kahler, Elisabeth M Oehrlein, Meredith Greer Baumgartner
Although the analysis of 'big data' holds tremendous potential to improve patient care, there remain significant challenges before it can be realized. Accuracy and completeness of data, linkage of disparate data sources, and access to data are areas that require particular focus. This article discusses these areas and shares strategies to promote progress. Improvement in clinical coding, innovative matching methodologies, and investment in data standardization are potential solutions to data validation and linkage problems...
May 4, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28470594/how-to-appropriately-extrapolate-costs-and-utilities-in-cost-effectiveness-analysis
#15
Laura Bojke, Andrea Manca, Miqdad Asaria, Ronan Mahon, Shijie Ren, Stephen Palmer
Costs and utilities are key inputs into any cost-effectiveness analysis. Their estimates are typically derived from individual patient-level data collected as part of clinical studies the follow-up duration of which is often too short to allow a robust quantification of the likely costs and benefits a technology will yield over the patient's entire lifetime. In the absence of long-term data, some form of temporal extrapolation-to project short-term evidence over a longer time horizon-is required. Temporal extrapolation inevitably involves assumptions regarding the behaviour of the quantities of interest beyond the time horizon supported by the clinical evidence...
May 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28456972/verification-of-decision-analytic-models-for-health-economic-evaluations-an-overview
#16
Erik J Dasbach, Elamin H Elbasha
Decision-analytic models for cost-effectiveness analysis are developed in a variety of software packages where the accuracy of the computer code is seldom verified. Although modeling guidelines recommend using state-of-the-art quality assurance and control methods for software engineering to verify models, the fields of pharmacoeconomics and health technology assessment (HTA) have yet to establish and adopt guidance on how to verify health and economic models. The objective of this paper is to introduce to our field the variety of methods the software engineering field uses to verify that software performs as expected...
April 29, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28455834/does-the-public-prefer-health-gain-for-cancer-patients-a-systematic-review-of-public-views-on-cancer-and-its-characteristics
#17
REVIEW
Liz Morrell, Sarah Wordsworth, Sian Rees, Richard Barker
BACKGROUND: Policies such as the Cancer Drugs Fund in England assumed a societal preference to fund cancer care relative to other conditions, even if that resulted in lower health gain for the population overall. OBJECTIVE: The aim of this study was to investigate the evidence for such a preference among the UK public. METHODS: The MEDLINE, PubMed and Econlit electronic databases were searched for studies relating to preferences for prioritising cancer treatment, as well as studies relating to preferences for the characteristics of cancer (severity of disease, end-of-life)...
April 29, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28432642/emerging-use-of-early-health-technology-assessment-in-medical-product-development-a-scoping-review-of-the-literature
#18
REVIEW
Maarten J IJzerman, Hendrik Koffijberg, Elisabeth Fenwick, Murray Krahn
Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Over the past 25 years it has been suggested that health economic evaluation in the early stages may benefit the development and diffusion of medical products...
April 21, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28391508/response-to-letter-to-the-editor-regarding-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#19
LETTER
Bram L T Ramaekers, Rob Riemsma, Florian Tomini, Thea van Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L Severens, Jos Kleijnen, Manuela A Joore
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28390016/comment-on-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-an-nice-single-technology-appraisal
#20
LETTER
Odette Reifsnider, Fiona Hall, Sonja Sorensen, Irina Proskorovsky, Isabelle Girod, Jennifer Lee
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"